Comparative Pharmacology
Head-to-head clinical analysis: NEO RX versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO RX versus XERAVA.
NEO-RX vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
100 mg intravenously every 12 hours.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Terminal elimination half-life is 2.5-3 hours in adults with normal renal function; increased to up to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinically, this supports 8-hourly dosing intervals in normal renal function, with extended intervals in renal impairment.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal excretion accounts for 90-100% of elimination, primarily as the parent drug via glomerular filtration and tubular secretion. Urinary excretion: 90-100% unchanged. Fecal/biliary: negligible (<2%).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic